GoAI
Get started
Whitehawk Therapeutics Inc logo

Whitehawk Therapeutics Inc

WHWK

NASDAQHealthcareBiotechnology

Open in GoAI

Latest quote

$4.72

−$0.10 · -2.07%

Aug 21, 3:55 PM ET

WHWK company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

24

Expensive

Momentum

56

Neutral

Sentiment

57

Mixed

Risk resilience

45

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Whitehawk Therapeutics Inc. is a biopharmaceutical enterprise currently undergoing clinical trials. This company specializes in crafting highly targeted treatment options for cancers that are identified by distinct genetic profiles.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
David J. Lennon
Listed since
Aug 1, 2017
Employees
32

Market position

Volume
226.21K
0.5× average
Average volume
450.82K
Average daily volume
Market cap
269.65M USD
Beta
0.78
Market reference 1

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
112.2M USD
EV / EBITDA
-5.47×
Earnings yield
-13.75%
Free cash flow yield
-65.43%

Profitability & efficiency

Return on equity
-15.11%
Return on assets
-13.66%
Return on invested capital
-83.93%

Financial health

Current ratio
10.26×
Altman Z-score
11.53
Piotroski F-score
1 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends1091%-2916%-6924%-10932%Gross margin, FY2021: -1656.25%Gross margin, FY2022: -123.43%Gross margin, FY2023: -112.44%Gross margin, FY2024: -108.04%Gross margin, FY2025: 89.36%Operating margin, FY2021: -9930.09%Operating margin, FY2022: -411.94%Operating margin, FY2023: -295.36%Operating margin, FY2024: -259.62%Operating margin, FY2025: -1601.12%Net margin, FY2021: -9829.46%Net margin, FY2022: -397.69%Net margin, FY2023: -270.04%Net margin, FY2024: -245.13%Net margin, FY2025: -288.26%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 -1656.25%. Gross margin FY2022 -123.43%. Gross margin FY2023 -112.44%. Gross margin FY2024 -108.04%. Gross margin FY2025 89.36%. Operating margin FY2021 -9930.09%. Operating margin FY2022 -411.94%. Operating margin FY2023 -295.36%. Operating margin FY2024 -259.62%. Operating margin FY2025 -1601.12%. Net margin FY2021 -9829.46%. Net margin FY2022 -397.69%. Net margin FY2023 -270.04%. Net margin FY2024 -245.13%. Net margin FY2025 -288.26%.

Income trends

Revenue

7.15M USD-72.50%

Operating income

−114.4M USD-69.59%

Net income

−20.6M USD+67.66%
Income trends across reported periods40.02M USD−16.13M USD−72.29M USD−128.44M USDRevenue, FY2021: 1.12M USDRevenue, FY2022: 15.22M USDRevenue, FY2023: 24.35M USDRevenue, FY2024: 25.98M USDRevenue, FY2025: 7.15M USDOperating income, FY2021: −111.22M USDOperating income, FY2022: −62.68M USDOperating income, FY2023: −71.93M USDOperating income, FY2024: −67.46M USDOperating income, FY2025: −114.4M USDNet income, FY2021: −110.09M USDNet income, FY2022: −60.51M USDNet income, FY2023: −65.77M USDNet income, FY2024: −63.69M USDNet income, FY2025: −20.6M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 1.12M USD. Revenue FY2022 15.22M USD. Revenue FY2023 24.35M USD. Revenue FY2024 25.98M USD. Revenue FY2025 7.15M USD. Operating income FY2021 −111.22M USD. Operating income FY2022 −62.68M USD. Operating income FY2023 −71.93M USD. Operating income FY2024 −67.46M USD. Operating income FY2025 −114.4M USD. Net income FY2021 −110.09M USD. Net income FY2022 −60.51M USD. Net income FY2023 −65.77M USD. Net income FY2024 −63.69M USD. Net income FY2025 −20.6M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue7.15M USD25.98M USD24.35M USD15.22M USD1.12M USD
Cost of goods sold760K USD54.05M USD51.74M USD34M USD19.67M USD
Gross profit6.39M USD−28.07M USD−27.38M USD−18.78M USD−18.55M USD
Research and development90.96M USD51.03M USD48.93M USD32.66M USD19.67M USD
Selling, general, and administrative29.82M USD36.75M USD44.55M USD40.18M USD18.51M USD
Operating expenses120.79M USD39.39M USD44.55M USD43.9M USD92.67M USD
Interest income6.23M USD3.93M USD6.4M USD2.4M USD13K USD
Interest expense—154K USD231K USD230K USD665K USD
Depreciation and amortization79K USD193K USD169K USD159K USD105K USD
Operating income−114.4M USD−67.46M USD−71.93M USD−62.68M USD−111.22M USD
Net income−20.6M USD−63.69M USD−65.77M USD−60.51M USD−110.09M USD

Company facts updated Aug 24, 2026.

Earnings

Latest fiscal-year EPS
-0.33
FY2025
Latest fiscal-year revenue
7.15M USD
FY2025 · -72.50% year over year

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual EPS trend0.88-3.95-8.79-13.62FY21FY22FY23FY24FY25

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual revenue trend28.47M18.52M8.58M-1.37MFY21FY22FY23FY24FY25

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$8.00

69.13% upside
Past 12 months12-month forecast

Price history unavailable

High $9.00Average $8.00Low $7.00

Corporate actions

Corporate action history

Stock split

Effective Aug 27, 2021

15:1

WHWK peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding WHWK

Funds reporting this stock among their holdings, ordered by reported position size.

iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
3.49M
Weight
0.00%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
3.42M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
1.81M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Value ETF logoiShares Russell 2000 Value ETFIWN
Market value
1.5M
Weight
0.01%
AUM
14.66B USD
Expense ratio
0.24%
Price / 1D
$224.81+0.45%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
699.33K
Weight
0.00%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
541.1K
Weight
0.04%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%
Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF logoGoldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSC
Market value
247.83K
Weight
0.02%
AUM
1.08B USD
Expense ratio
0.20%
Price / 1D
$91.32+0.82%
Avantis U.S. Small Cap Equity ETF logoAvantis U.S. Small Cap Equity ETFAVSC
Market value
246.61K
Weight
0.01%
AUM
3.16B USD
Expense ratio
0.25%
Price / 1D
$73.84+0.70%

Continue in GoAI

Research WHWK

research.disclaimer